Breadcrumb

Breadcrumbs

Press Releases

Press Releases

News, Events, Updates, Breakthroughs

Journalists may direct questions to mediainquiries@dsi.com. Or click here for direct contact information for Daiichi Sankyo U.S. Public Affairs team

Press announcements are archived by release date, searchable by topic:

From To
Date Title
Mon Dec 11 00:00:00 GMT-04:00 2017
Daiichi Sankyo Presents Phase 1 Data for EZH1/2 Dual Inhibitor DS-3201 in Patients with Non-Hodgkin ...
PDF (252 KB)
Thu Dec 07 00:00:00 GMT-04:00 2017
Daiichi Sankyo Presents Updated Data for DS-8201 in Patients with HER2-Expressing Breast Cancer at ...
PDF (190 KB)
Fri Dec 01 00:00:00 GMT-04:00 2017
Daiichi Sankyo and Translational Sciences Conclude Agreement, after Successful Phase 1a Trial, as ...
PDF (194 KB)
Mon Nov 20 00:00:00 GMT-04:00 2017
Daiichi Sankyo Initiates Pivotal Phase 2 Study of DS-8201 in Patients with HER2-Positive Advanced G ...
PDF (183 KB)
Mon Nov 20 00:00:00 GMT-04:00 2017
Daiichi Sankyo, Inc. Launches CommitmentsinPainCare.com
PDF (327 KB)
Tue Nov 14 00:00:00 GMT-04:00 2017
Data at SABCS and ASH Demonstrate Daiichi Sankyo Commitment to Advancing Science in Breast and Bloo ...
PDF (195 KB)
Wed Nov 08 00:00:00 GMT-04:00 2017
Daiichi Sankyo, Inc., Announces New Analyses of Once-Daily SAVAYSA® (edoxaban) to be Presented at t ...
PDF (214 KB)
Fri Nov 03 00:00:00 GMT-04:00 2017
Daiichi Sankyo, Inc. and Inspirion Delivery Sciences LLC Announce U.S. Availability of MorphaBond™ ...
PDF (289 KB)
Tue Oct 31 00:00:00 GMT-04:00 2017
Daiichi Sankyo Announces ENLIVEN Phase 3 Study of Pexidartinib Met Primary Endpoint in Tenosynovial ...
PDF (152 KB)
Mon Oct 30 00:00:00 GMT-04:00 2017
Daiichi Sankyo and Glycotope Announce Option Agreement for Antibody Drug Conjugate Strategic Collab ...
PDF (239 KB)
Showing 1 - 10 of 42 results.

Press Release More Stories

More Stories

Who We Are

As the U.S. subsidiary of a global pharmaceutical innovator, Daiichi Sankyo, Inc. draws on a rich heritage of innovation, integrity and accountability..

read more ...